Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis
Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms SAN DIEGO, June 19, 2026 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology...
Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms SAN DIEGO, June 19, 2026 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.